Viewing Study NCT05025735


Ignite Creation Date: 2025-12-24 @ 10:20 PM
Ignite Modification Date: 2026-02-23 @ 8:57 PM
Study NCT ID: NCT05025735
Status: UNKNOWN
Last Update Posted: 2021-10-19
First Post: 2021-06-26
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Alpelisib, Fulvestrant and Dapagliflozin for the Treatment of HR+, HER2 -, PIK3CA Mutant Metastatic Breast Cancer
Sponsor: Saint Luke's Health System
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Metastatic Breast Cancer View
None HER2-negative Breast Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Metastatic Breast Cancer View
None HER2 Negative View
None HR Positive View